Model performance
| Model . | Features∗ . | AUC training cohort (95% CI) . | CV-AUC training cohort (95% CI) . | AUC validation cohort (95% CI) . |
|---|---|---|---|---|
| Clinical | Ann Arbor stage B symptoms R/R status | 0.787 (0.692-0.883) | 0.729 (0.724 - 0.734) | 0.677 (0.535-0.819) |
| Radiomics SUV 4.0 | No. of lesions VolSpread TLRSUVmean | 0.719 (0.605-0.833) | 0.691 (0.685-0.696) | 0.721 (0.580-0.863) |
| Final model | R/R status B symptoms MTV Spread TLRSUVmean | 0.837 (0.744-0.930) | 0.810 (0.805-0.814) | 0.750 (0.627-0.872) |
| P value of clinical vs final model† | .00094 | .0049 | <.0001 | |
| Model . | Features∗ . | AUC training cohort (95% CI) . | CV-AUC training cohort (95% CI) . | AUC validation cohort (95% CI) . |
|---|---|---|---|---|
| Clinical | Ann Arbor stage B symptoms R/R status | 0.787 (0.692-0.883) | 0.729 (0.724 - 0.734) | 0.677 (0.535-0.819) |
| Radiomics SUV 4.0 | No. of lesions VolSpread TLRSUVmean | 0.719 (0.605-0.833) | 0.691 (0.685-0.696) | 0.721 (0.580-0.863) |
| Final model | R/R status B symptoms MTV Spread TLRSUVmean | 0.837 (0.744-0.930) | 0.810 (0.805-0.814) | 0.750 (0.627-0.872) |
| P value of clinical vs final model† | .00094 | .0049 | <.0001 | |
Spread, the sum of the distances between all lesions; TLRSUVmean, tumor-to-liver ratio of the lesion SUVmean and liver SUVmean; VolSpread, the sum of differences in volume between all lesions.
All radiomics variables are log transformed.
P values represent the added value of the radiomics features to the clinical model. P value of the cross-validated (CV)-AUC represents the median P value of 2000 repeats of fivefold of cross-validation.